Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekSTAT News ↗
Democrats are mapping out their post-election strategy, and see health care probes as a winning issue.…
The WeekBioPharma Dive ↗
A Lutathera copycat has become the first "radioligand equivalent" cleared by regulators. Elsewhere, Novo dropp…
The WeekPharmaVoice ↗
Revolution's pancreatic cancer approval marked a milestone in RAS-targeted treatment. Now, new treatments from…
The WeekFiercePharma ↗
As the FDA marches toward the likely first approval of a psychedelic medicine, the agency today convened a hea…
The WeekFierceBiotech ↗
Novo's attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from…
The WeekBriefing
STAT reported that new documents show a rushed Medicare AI prior authorization pilot led to delayed care in so…
The WeekSTAT News ↗
The drug stabilized kidney function and reduced the risk of death and other complications in IgAN patients…
The WeekDrug Channels ↗
On October 12, 2026, Drug Channels Institute will release our 2026-27 Economic Report on Pharmaceutical Wholes…
The WeekBioPharma Dive ↗
As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed …
The WeekPharmaVoice ↗
The reauthorization could give Congress the opportunity to help streamline clinical trials and accelerate drug…
The WeekFiercePharma ↗
A preliminary 15% higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo's bi…
The WeekFierceBiotech ↗
MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer…
The WeekBriefing
GSK is preparing a first-line FDA submission for Jideytro in lung cancer. The move would mark a major step for…
The WeekDrug Channels ↗
Informa Connect's Pharma/Biotech GTN Summit November 16-18, 2026 | Hilton at Penn's Landing, Philadelphia, PA,…
The WeekPharmaVoice ↗
How auditable LCA data can guide more informed sustainability decisions.…
The WeekSTAT News ↗
Novo Nordisk is now going by Novo, part of a rebrand that the company hopes can signal a more focused, competi…
The WeekFiercePharma ↗
Newly revealed global phase 3 data from Merck and Gilead's failed Trodelvy first-line non-small cell lung canc…
The WeekFierceBiotech ↗
GSK's risvutatug rezetecan has achieved a median overall survival of 18.5 months in a phase 3 trial, painting …
The WeekBriefing
Karyopharm secured an extra month to negotiate with creditors or seek a deal. The same weekly tape also pointe…
The WeekFiercePharma ↗
Following formal sign-off from the FDA, Handa Pharmaceuticals' branded drug reformulation strategy has paid of…
The WeekFierceBiotech ↗
The FDA has delayed its approval decision for Exelixis' oral kinase inhibitor in combination with Roche's Tece…
The WeekBriefing
Members of the American Diabetes Association are escalating a June conference dispute into a broader boycott. …
The WeekSTAT News ↗
A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could…
The WeekSTAT News ↗
An E.U. AG recommended annulling part of a directive that requires drugmakers to finance 80% of the costs of w…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.